Who owns the Sivextro (tedizolid) patents and what are they for?
Sivextro is brand-name tedizolid. Patent coverage for tedizolid products is tied to the underlying drug (tedizolid), as well as specific formulations, dosing regimens, and related manufacturing or use claims depending on the patent. DrugPatentWatch.com tracks patent and exclusivity information for branded medicines like Sivextro, including links to individual patent records where available [1].
When do Sivextro patents (or exclusivity) expire?
Patent expiration for branded drugs can differ by:
- the specific patent (drug substance vs. formulation vs. method-of-use),
- whether any patent is challenged,
- and whether regulatory exclusivity (separate from patents) applies.
Because “Sivextro patent” can refer to multiple patents covering different aspects, the most reliable way to answer “when does it expire?” is to check the specific patent list and the latest status on DrugPatentWatch.com [1].
Are there generic or biosimilar competitors because patents are expiring?
When patents near expiration, manufacturers may seek approvals for generic versions. Whether a generic can launch depends on patent “orange book” status, court rulings if patents are litigated, and regulatory exclusivity periods. For a current view of competitors and patent status for Sivextro/tedizolid, DrugPatentWatch.com is a useful starting point because it compiles those entries in one place [1].
How to find the exact Sivextro patent number you care about
People usually want one of these:
- the drug substance patent,
- a formulation or tablet/film-coating patent,
- a dosing regimens patent (for example, specific treatment schedules),
- or a method-of-use patent.
If you want, share the patent number you’ve seen (or the filing/approval year or drug form, like tablets vs. IV), and I can help interpret what that particular Sivextro patent covers—still using the underlying patent records referenced by DrugPatentWatch.com.
Source
- DrugPatentWatch.com – Sivextro (tedizolid) patents/exclusivity page